Drugs / JMT601
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04853329 | Dec 2021 → Jan 2023 | B-cell non-Hodgkin lymphoma | Conjupro Biotherapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT06725524 | Oct 2021 → Dec 2025 overdue | B-cell non-Hodgkin lymphoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07029139 | Jun 2025 → Apr 2027 expected | idiopathic membranous glomerulonephritis | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMT601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07029139 ↗ |
| Known as | CPO107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04853329 ↗ |
| Route | Intravenous | “Study of CPO107 Administered Intravenously to Patients With Advanced CD20-positive Non Hodgkins Lymphoma” NCT04853329 ↗ |